(BUSINESS WIRE)– NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, …
Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of $40, which represents a potential upside …
In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $41 price …
In a research report issued Thursday, Wedbush analyst David Nierengarten maintained an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of …
In a report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $37 fair value, following last friday’s news …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $41 price …
In a research note published yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharma (NASDAQ:NPSP) with a $37 fair …
In a report published yesterday, Wedbush analyst David Nierengarten assigned an Outperform rating on NPS Pharmaceuticals Inc. (NASDAQ:NPSP) ahead of the release of the …
In a research report released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) with a $37 fair value, ahead of the company’s upcoming …
In a research report released yesterday, Janney Capital analyst Kimberly Lee reiterated a Buy rating on NPS Pharmaceuticals (NPSP) with a $37 fair …
